EUVIMEDEUVIMED entdecken
Leserbrief

Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system ( FAERS ) from 2022 to 2023

Hannah Godfrey iD, Zachary Leibovit-Reiben iD, Patrick Jedlowski, Rebecca Thiede

Journal of the European Academy of Dermatology and Venereology · 2025-02 · 39 (2)

DOI: 10.1111/jdv.20197 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 24.06.2024. Verfasst von Hannah Godfrey und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA.
  • Division of Dermatology, University of Arizona College of Medicine-Tucson, Tucson, Arizona, USA.

ORCID-Profile: Hannah Godfrey, Zachary Leibovit-Reiben

Zitieren

APA

Godfrey, H., Leibovit-Reiben, Z., Jedlowski, P., & Thiede, R. (2025). Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system ( FAERS ) from 2022 to 2023. Journal of the European Academy of Dermatology and Venereology, 39(2). https://doi.org/10.1111/jdv.20197

Vancouver

Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system ( FAERS ) from 2022 to 2023. Journal of the European Academy of Dermatology and Venereology. 2025;39(2). doi:10.1111/jdv.20197

BibTeX
@article{Godfrey2025,
  author = {Godfrey, Hannah and Leibovit-Reiben, Zachary and Jedlowski, Patrick and Thiede, Rebecca},
  title = {Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system ( FAERS ) from 2022 to 2023},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  volume = {39},
  number = {2},
  doi = {10.1111/jdv.20197}
}
Kostenlos starten →